Business Wire

Xsolla is Highlighting New Features and Game Industry Shifts at GDC 2022

Share

Xsolla, a global video game commerce company, is attending and presenting at GDC (Game Developers Conference), the biggest game conference in the world, today through March 25th in San Francisco, California, USA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005435/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Meet us at GDC 2022 (Graphic: Business Wire)

Xsolla is hosting six informative speaking sessions on Tuesday, March 22nd, including a keynote from President Chris Hewish. Additionally, Xsolla is exhibiting at Moscone South S657, starting on Wednesday, March 23rd, where attendees can meet with Xsolla experts and get a preview of the latest products and solutions designed to accelerate video game commerce in 2022.

“I’m excited to return to GDC in person and to kick off Xsolla’s series of trending topic speaker sessions,” Hewish said. “It’s great to see old friends and meet new people from all over the world who share our passion for video games.”

The Xsolla team is sharing industry updates and their expertise on the tools and services available for video game developers and publishers. Topics will range from mobile game monetization outside of the app store, payments for the enterprise, and token-based systems for digital content with a new NFT Checkout to emerging market opportunities and prelaunch funding. Video-on-demand of the sessions will be available later in the week for those who could not attend to watch and learn.

Tuesday, March 22 | 9:30am - 10:30am [Add to iCal]
GOING GLOBAL, STAYING LOCAL: HELPING GAME DEVELOPERS SUCCEED
Great games don’t just appear. They start as ideas, and only through the curiosity, dedication, and grit of people all over the globe do they come to life. Xsolla President Chris Hewish outlines ways to ensure that every developer has the same opportunity to see their game become a part of how we play.

Tuesday, March 22 | 10:50am - 11:50am [Add to iCal]
INSIDE THE WALLED PAYMENT GARDEN: A GUIDE TO MOBILE MARKET FREEDOM
In this session, Anthony Mendoza and Miikka Luotio share a frank discussion on how developers can break into mobile gaming's 'walled payment garden' and grow their games just as many others have already done.

Tuesday, March 22 | 1:20pm - 1:50pm [Add to iCal]
GAME OF FUNDS: SUCCESS IS COMING
Xsolla’s dynamic duo of funding, Justin Berenbaum and Lily Goldner, host special guests David Martinez from Raw Fury and Ken Seto from Massive Damage Games in a fireside chat, where you’ll discover how to improve your chances and create business alliances.

Tuesday, March 22 | 2:10pm - 2:40pm [Add to iCal]
BEYOND CREDIT: TAKING ADVANTAGE OF EMERGING PAYMENT METHODSWORLDWIDE
"Cash, check or charge?" It used to be that these were the only options when handling payments. Now there are hundreds. Berkley Egenes leads a team of Xsolla regional experts as they discuss how to control the chaos and take advantage of emerging payment methods around the globe.

Tuesday, March 22 | 3:00pm - 3:30pm [Add to iCal]
"THINGS I WISH I KNEW SOONER" ABOUT THE GAME INDUSTRY
Xsolla's Sam Gaglani hosts a panel of games industry pros, including Kara Bilkiss from Rogue Games, Michael Lewis from Take-Two Interactive, and Andreea Enache from Secret Society Games who've "been there, done that" as they share their wisdom and insights. They will focus on topics that affect developers at any studio and discuss things they wish they had known sooner about working in the industry.

Tuesday, March 22 | 3:50pm - 4:20pm [Add to iCal]
HYBRID TIMES: GAME DEVELOPERS SOUND OFF ON WORKING FROM HOME, COMPENSATION, AND CAREER
The industry-leading platform 80 Level asked the gaming community about recent challenges and opportunities, and over 800 game developers shared their experiences. Kirill Tokarev, Editor in Chief at 80 Level, highlights what these responses reveal about our past and what the future has in store.

Book a meetingwith Xsolla’s global game commerce experts to discover how they can help expand your video game commerce in the changing games industry.

For more informationon how to attend speaking sessions and connect with Xsolla at GDC 2022, visit https://xsolla.com/gdc2022

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world to support major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information and to learn more, please visit xsolla.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Viktoria Rogozhnikova
v.rogozhnikova@xsolla.com

Web: www.xsolla.com
Email: business@xsolla.com
Press Inquiries - press@xsolla.com
Facebook: https://www.facebook.com/xsolla.inc
Instagram: https://www.instagram.com/xsolla/
LinkedIn: https://www.linkedin.com/company/xsolla
Twitter: https://twitter.com/xsolla

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom